Johnson & Johnson has reached its limit for free report views. Key Accomplishments. PDF; Form 10K (HTML) Johnson & Johnson does not currently have any hardcopy reports on AnnualReports.com. 0000028777 00000 n Johnson & Johnson’s operating earnings increased from 2017 to 2018 and from 2018 to 2019. 0000005225 00000 n 0000061178 00000 n Ten years of annual and quarterly financial statements and annual report data for Johnson & Johnson (JNJ). 0000007598 00000 n • We delivered strong operational revenue and adjusted operational earnings growth* that exceeded the financial performance goals we set for the Company at the start of 2019. 2016 Annual Report. Johnson & Johnson Annual Meeting Thursday, April 23, 2020, 10:00 a.m. Register for the Virtual Annual Meeting of Shareholders View and Download the 2020 Proxy Statement View and Download the 2019 Annual Report Visit the 2019 Digital Year in Review The reader is cautioned not to rely on these forward-looking statements. View JNJ financial statements in full, including balance sheets and ratios. “We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. 0000006784 00000 n Other modeling considerations will be provided on the webcast. 0000021459 00000 n 0000062444 00000 n 0000005032 00000 n 0000039380 00000 n “We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. Download PDF. Medical DevicesWorldwide Medical Devices operational sales, excluding the net impact of acquisitions and divestitures grew 3.2%* driven by the growth of electrophysiology products in the Interventional Solutions business, endocutters and international energy products in the Advanced Surgery business. View JNJ financial statements in full. Supplemental Sales Data 31.6 KB. Earnings Presentation 1.8 MB. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2018, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Download PDF. All Rights Reserved. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results. Find out the revenue, expenses and profit or loss over the last fiscal year. • We again made record investments in research We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. 0000008488 00000 n 0000045254 00000 n 0000016636 00000 n Pharmaceutical Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures grew 4.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, OPSUMIT (macitentan), an oral endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to delay disease progression, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with non-metastatic castration-resistant prostate cancer and PREZISTA/PREZCOBIX/REZOLSTA/ SYMTUZA (D/C/F/TAF) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, partially offset by declines in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer due to biosimilar and generic entrants. “Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. 2018 Annual Meeting Materials. 2017 Proxy Statement. EEO Is the Law | EEO Is the Law GINA Supplement | Do Not Sell My Personal Information, New Brunswick, N.J. (July 16, 2019) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2019. Q4. Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. 0000044138 00000 n 0000018562 00000 n 0000076006 00000 n 0000005269 00000 n 0000044867 00000 n 2017 Annual Meeting Materials. Click the button below to request a report when hardcopies become available. 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: July 2019 = $1.12; Euro Average Rate: April 2019 = $1.12 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson Reports 2018 Fourth-Quarter … NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. As previously disclosed, the divestiture of the ASP business was completed, resulting in an approximate $2.0 billion pretax gain in the quarter. 0000043740 00000 n Johnson & Johnson Medical Devices Companies, IMBRUVICA (ibrutinib) – CHMP Positive Opinions in combination with obinutuzumab in CLL and in combination with rituximab in WM, DARZALEX (daratumumab) – Newly diagnosed patients with Multiple Myeloma in combination with Lenalidomide and Dexamethasone (U.S.), DARZALEX (daratumumab) – Subcutaneous formulation in multiple myeloma (U.S.), ERLEADA (apalutamide) - Metastatic Hormone-Sensitive Prostate Cancer (EU), ERLEADA (apalutamide) – Metastatic Castration - Sensitive Prostate Cancer (U.S), Rilpivirine and Cabotegravir - Monthly, Injectable, Two-Drug Regimen for Treatment of HIV. 0000065210 00000 n Shipping Information. Johnson & Johnson Reports 2019 First-Quarter Results 311.5 KB. 0000021598 00000 n 0000047903 00000 n 0000023453 00000 n 0000010746 00000 n 0000062836 00000 n Request Information. You can search for filings below. 0000060832 00000 n 0000020834 00000 n These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises.